Acquisition Agreement for Paras Pharmaceuticals -- Current
Dealdoc Acquisition agreement for Paras Pharmaceuticals Paras Pharmaceuticals Reckitt Benckiser Dec 13 2010 © 2009-2021, Wildwood Ventures Ltd. All rights reserved. Acquisition agreement for Paras Pharmaceuticals Paras Pharmaceuticals Companies: Reckitt Benckiser Announcement date: Dec 13 2010 Deal value, US$m: 730.0 : acquisition value • Details • Financials • Termsheet • Press Release • Filing Data • Contract Details Announcement date: Dec 13 2010 Pharmaceutical Industry sectors: Consumer health Financials Deal value, US$m: 730.0 : acquisition value Termsheet 13 December 2010 Reckitt Benckiser has agreed to buy Paras forINR 32.6 billion (Indian Rupees) (approximately GBP 460 million). RB will finance the transaction from existing facilities. Press Release RB Buys India’s Paras Pharmaceuticals Ltd 13 December 2010 Reckitt Benckiser Group plc (RB) today announces that it has agreed to buy Paras Pharmaceuticals Limited (Paras) forINR 32.6 billion (Indian Rupees) (approximately GBP 460 million) from the current shareholders, including the Patel family and Actis, the emerging markets private equity investor. RB will finance the transaction from existing facilities. Paras is a privately-owned Indian company with a portfolio of leading Indian over the counter Health and Personal Care brands including: Moov, the No 2 topical analgesic pain ointment, D’Cold, the No 2 cold & flu remedy, Dermicool, the No 2 for prickly heat, Krack, the No 1 medicated skin treatment for cracked heels and Itch Guard and Ring Guard anti fungal creams. In addition, Paras has a personal care business led by Set Wet, a leading hair gel and deodorant brand. In the fiscal year ending March 2010, Paras generated net sales of INR 4,014 million, representing a mid-teens average growth rate over the last four years, and operating EBITDA for the same year of INR 1,083 million (approximately GBP 56 million and GBP 15 million respectively).
[Show full text]